Kiniksa Pharmaceuticals Stock Price on December 31, 2023
| KNSA Stock | USD 21.41 0.09 0.42% |
Below is the normalized historical share price chart for Kiniksa Pharmaceuticals extending back to May 24, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Kiniksa Pharmaceuticals stands at 21.41, as last reported on the 12th of December 2024, with the highest price reaching 21.91 and the lowest price hitting 21.26 during the day.
If you're considering investing in Kiniksa Stock, it is important to understand the factors that can impact its price. Kiniksa Pharmaceuticals has Sharpe Ratio of -0.0757, which conveys that the firm had a -0.0757% return per unit of risk over the last 3 months. Kiniksa Pharmaceuticals exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kiniksa Pharmaceuticals' Mean Deviation of 1.88, risk adjusted performance of (0.03), and Standard Deviation of 2.86 to check out the risk estimate we provide.
At present, Kiniksa Pharmaceuticals' Total Stockholder Equity is projected to decrease significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 552.6 M, whereas Common Stock Total Equity is forecasted to decline to about 13.4 K. . At present, Kiniksa Pharmaceuticals' Price Earnings Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Book Value Ratio is expected to grow to 2.94, whereas Price To Sales Ratio is forecasted to decline to 4.32. Kiniksa Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 24th of May 2018 | 200 Day MA 21.9221 | 50 Day MA 23.5489 | Beta 0.348 |
Kiniksa |
Sharpe Ratio = -0.0757
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | KNSA |
Estimated Market Risk
| 2.89 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kiniksa Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kiniksa Pharmaceuticals by adding Kiniksa Pharmaceuticals to a well-diversified portfolio.
Price Book 3.5109 | Enterprise Value Ebitda (44.93) | Price Sales 3.9945 | Shares Float 15.3 M | Wall Street Target Price 36 |
Kiniksa Pharmaceuticals Valuation on December 31, 2023
It is possible to determine the worth of Kiniksa Pharmaceuticals on a given historical date. On December 31, 2023 Kiniksa was worth 17.85 at the beginning of the trading date compared to the closed value of 17.54. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Kiniksa Pharmaceuticals stock. Still, in general, we apply an absolute valuation method to find Kiniksa Pharmaceuticals' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Kiniksa Pharmaceuticals where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Kiniksa Pharmaceuticals' related companies.
| Open | High | Low | Close | Volume | |
| 18.62 | 18.65 | 17.76 | 17.85 | 449,342 | |
12/29/2023 | 17.85 | 17.85 | 17.21 | 17.54 | 913,594 |
| 17.61 | 19.62 | 17.61 | 18.53 | 608,480 |
| Backtest Kiniksa Pharmaceuticals | | | Kiniksa Pharmaceuticals History | | | Kiniksa Pharmaceuticals Valuation | Previous | Next |
Kiniksa Pharmaceuticals Trading Date Momentum on December 31, 2023
| On January 02 2024 Kiniksa Pharmaceuticals was traded for 18.53 at the closing time. The top price for the day was 19.62 and the lowest listed price was 17.61 . The trading volume for the day was 608.5 K. The trading history from January 2, 2024 was a factor to the next trading day price jump. The trading delta at closing time against the next closing price was 5.64% . The trading delta at closing time against the current closing price is 3.76% . |
Kiniksa Pharmaceuticals Fundamentals Correlations and Trends
By evaluating Kiniksa Pharmaceuticals' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Kiniksa Pharmaceuticals' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Kiniksa financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Kiniksa Pharmaceuticals Stock history
Kiniksa Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Kiniksa is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Kiniksa Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Kiniksa Pharmaceuticals stock prices may prove useful in developing a viable investing in Kiniksa Pharmaceuticals
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 71.9 M | 57.9 M | |
| Net Income Applicable To Common Shares | 210.9 M | 221.4 M |
Kiniksa Pharmaceuticals Quarterly Net Working Capital |
|
Kiniksa Pharmaceuticals Stock Technical Analysis
Kiniksa Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Kiniksa Pharmaceuticals Period Price Range
Low | December 12, 2024
| High |
0.00 | 0.00 |
Kiniksa Pharmaceuticals cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Kiniksa Pharmaceuticals December 12, 2024 Market Strength
Market strength indicators help investors to evaluate how Kiniksa Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kiniksa Pharmaceuticals shares will generate the highest return on investment. By undertsting and applying Kiniksa Pharmaceuticals stock market strength indicators, traders can identify Kiniksa Pharmaceuticals entry and exit signals to maximize returns
Kiniksa Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Kiniksa Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Kiniksa Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Kiniksa to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.60) | |||
| Treynor Ratio | (0.28) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |